Thyroid cancer molecular signaling pathways and use of targeted therapy

Endocrinol Metab Clin North Am. 2007 Sep;36(3):839-53, viii. doi: 10.1016/j.ecl.2007.06.001.

Abstract

Several agents are currently being tested that target thyroid molecular signaling and cancer cell biology. The pathways involved include but are not limited to the Ras pathway, vascular endothelial growth factor and epidermal growth factor receptors and antibodies, angiogenesis inhibitors, tyrosine kinase inhibitors, heat shock protein inhibitors, demethylating agents, histone deacetylase inhibitors, and gene therapy. Each of these targeted approaches holds promise for our future ability to treat patients with thyroid cancer unresponsive to traditional therapy.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Apoptosis / drug effects
  • Enzyme Inhibitors / therapeutic use
  • Genes, Transgenic, Suicide
  • Genetic Therapy
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors
  • Histone Deacetylase Inhibitors
  • Humans
  • PPAR gamma / agonists
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Signal Transduction*
  • Thyroid Neoplasms / drug therapy
  • Thyroid Neoplasms / metabolism*
  • Thyroid Neoplasms / therapy*
  • ras Proteins / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Enzyme Inhibitors
  • HSP90 Heat-Shock Proteins
  • Histone Deacetylase Inhibitors
  • PPAR gamma
  • Protein-Tyrosine Kinases
  • ras Proteins